Evotec AG has signed a partnership agreement with the Debiopharm Group of Switzerland to discover and develop novel compounds for the treatment of multiple forms of solid tumours and leukaemias which have defined genetic alterations. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
